Hepatic profile analyses of tipranavir in Phase II and III clinical trials

BACKGROUND: The risk and course of serum transaminase elevations (TEs) and clinical hepatic serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID recipients, who also received additional combination antiretroviral treatment agents in clinical trials (TPV/r-ba...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mikl, Jaromir, Sulkowski, Mark S, Benhamou, Yves, Dieterich, Douglas, Pol, Stanislas, Rockstroh, Jürgen, Robinson, Patrick A, Ranga, Mithun, Stern, Jerry O
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2803791/
https://ncbi.nlm.nih.gov/pubmed/20003457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-9-203
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados